Compositions for promoting immune checkpoint inhibitor therapy

JP7828386B2Active Publication Date: 2026-03-11MEIJI CO LTD
View PDF 10 Cites 0 Cited by

Patent Information

Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Filing Date
2024-05-15
Publication Date
2026-03-11

AI Technical Summary

Technical Problem

Immune checkpoint inhibitor therapy, while effective in activating the patient's immune system against tumors, has a low response rate due to multiple immune checkpoints and requires higher doses to achieve therapeutic efficacy.

Method used

A composition containing exopolysaccharides (EPS) from lactic acid bacteria, particularly Lactobacillus delbrueckii subsp. bulgaricus, enhances immune checkpoint inhibitor therapy by increasing CCR6-positive CD8+ T cells, promoting immune activation against tumors.

Benefits of technology

The EPS composition significantly enhances the therapeutic effects of immune checkpoint inhibitors, increasing CCR6-positive CD8+ T cells and suppressing tumor growth, thereby improving the response rate and reducing the required dosage.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007828386000001
    Figure 0007828386000001
  • Figure 0007828386000002
    Figure 0007828386000002
  • Figure 0007828386000003
    Figure 0007828386000003
Patent Text Reader

Abstract

To provide compositions for enhancing CCR6-positive CD8+T cells.SOLUTION: The present invention provides a composition for enhancing CCR6-positive CD8+T cells, comprising an exopolysaccharide of a lactic acid bacterium. The most preferable example of the lactic acid bacterium is a Lactobacillus bacterium.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Autoimmune disease preventive composition

    JP2000247895A

  • NK cell activator

    JP2005194259A

  • Lactobacillus having immunomodulating activity

    JP2005333919A

  • Immunomodulatory composition comprising Lactobacillus pentosus

    JP2008501013A

  • Composition and method for cancer immunotherapy

    JP2012211196A